baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

JP Morgan Put 125 BIIB 21.03.2025/ DE000JF2UD61 /

1/24/2025 9:48:00 AM	Chg.-0.020	Bid10:00:34 PM	Ask10:00:34 PM	Underlying	Strike price	Expiration date	Option type
0.240EUR	-7.69%	- Bid Size: -	- Ask Size: -	Biogen Inc	125.00 USD	3/21/2025	Put

TeleTrader 1/14 Wall Street closes mostly higher with earnings in sight

TeleTrader 10/30/2024 US opens lower after earnings, jobs, GDP data

TeleTrader 10/30/2024 Biogen's Q3 revenue down 3% to $2.5 billion

Newsfile Corp 10/10/2024 SAGE INVESTOR ALERT: Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to L...

GlobeNewswire 9/1/2024 SAGE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Invest...

GlobeNewswire 8/29/2024 SAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investo...

GlobeNewswire 8/26/2024 Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encoura...

GlobeNewswire 8/22/2024 Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...

GlobeNewswire 8/19/2024 Tiziana Life Sciences Appoints New Chief Executive Officer

GlobeNewswire 8/19/2024 Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief ...

GlobeNewswire 8/15/2024 Soleno Therapeutics Announces Updates to its Board of Directors

GlobeNewswire 8/15/2024 Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...

GlobeNewswire 8/8/2024 Royalty Pharma Reports Second Quarter 2024 Results

GlobeNewswire 8/1/2024 C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

TeleTrader 8/1/2024 Biogen books $2.5 billion in Q2 revenue

GlobeNewswire 8/1/2024 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire 7/31/2024 Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease

GlobeNewswire 7/30/2024 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...

GlobeNewswire 7/30/2024 Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fun...

GlobeNewswire 7/30/2024 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...

GlobeNewswire 7/26/2024 CVS Health Corporation Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law...

GlobeNewswire 7/26/2024 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

GlobeNewswire 7/26/2024 BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockh...

GlobeNewswire 7/22/2024 Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Fir...

GlobeNewswire 7/22/2024 DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of...

JP Morgan Put 125 BIIB 21.03.2025/ DE000JF2UD61 /

If you wish to receive reply to your feedback, please provide your email address.